Whilst no definitive statement on PKCβ D427N driver action in ATLL can be made without insight into the underlying molecular mechanism(s), the in vivo, cellular and biochemical evidence here indicates that this frequent PKCβ mutation is a gain-of-function mutation albeit with an altered substrate repertoire. The gene discussed is PRKCB; the disease is adult T-cell leukemia/lymphoma.